Fig. 2: Dynamic BH3 profiling predicts synergistic combinations with vincristine and BH3 mimetics in the CW9019 cell line. | Cell Death & Disease

Fig. 2: Dynamic BH3 profiling predicts synergistic combinations with vincristine and BH3 mimetics in the CW9019 cell line.

From: Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance

Fig. 2: Dynamic BH3 profiling predicts synergistic combinations with vincristine and BH3 mimetics in the CW9019 cell line.

a Results from the contribution of each anti-apoptotic protein: BCL-2/BCL-xL dependence BAD peptide; BCL-xL dependence HRK peptide; and MCL-1 dependence MS1 peptide in acquiring resistance to vincristine 1 nM treatment. Results expressed as ∆% priming represents the increase in priming compared to control cells. HRK and MS1 BH3 peptides showed a significant increase, indicating BCL-xL and MCL-1 adaptation, respectively. b Cell death from Annexin V and propidium iodide staining FACS analyses after 96 h incubation of CW9019 cells with single agents or the combination of vincristine (1 nM) with the corresponding BH3 mimetics S63845 (1 µM) and A-1331852 (0.1 µM) for 96 h. Values indicate mean values ± SEM from at least three independent experiment. **p < 0.01, *p < 0.05 compared to single agents and # indicates CI < 1.

Back to article page